Co-Processed Avicel®

Synergies to Simplify Formulation Challenges, Reduce Operational Costs

What is it?

Avicel® Microcrystalline Cellulose (MCC) has earned its place in countless solid dosage formulations for decades. As formulators work on different active ingredients, different delivery systems and different formulations, an offering of single form of MCC was not good enough. That is why we have introduced a wide range of Co-processed excipients using Avicel® which not only imparts superior functionality but also reduces operational costs.

Benefits

  • Improved process robustness, tablet hardness, and yields
  • Excellent recompactability, resulting in enhanced tableting performance and fewer rejected tablets
  • Exhibits less sensitivity to lubrication
  • Unparalleled suspension stability and functional versatility
  • Similar disintegration and dissolution - Avicel® Co-processed polymers offer exceptional performance in dry granulation processing, while maintaining fundamental requirements for disintegration and dissolution
  • Avicel® CE-15 in chewable tablets imparts overall sensory experience and perceived taste
  • Increased Process Efficiency - Avicel® DG improves roller compaction by enabling continuous processing and eliminating extra granular excipients

Get Started

DuPont cares about your privacy. Your personal information (name, email, phone number and other contact data) will be stored in chosen customer systems primarily hosted in the United States. This information will be used by DuPont, its affiliates, partners, and selected third parties in other countries to provide you with the product or service information requested. To learn more, please visit www.privacy.dupont.com. By providing your personal information, you agree to the terms and conditions of this Privacy Statement.